Neutral
This article examines three high-yield healthcare stocks—Pfizer, AbbVie, and Medtronic—detailing their unique dividend profiles and business models fo...
Neutral
AbbVie's latest quarterly results show a continued transition away from its former blockbuster drug Humira, with significant growth from immunology dr...
Bullish
Evercore ISI has slightly lowered its price target for AbbVie (ABBV) from $236 to $235, while maintaining an 'Outperform' rating. This adjustment foll...
Bullish
TD Private Client Wealth LLC reduced its stake in AbbVie Inc. by 12.6% in the fourth quarter, selling 9,822 shares to hold 68,073 shares valued at app...
Bullish
The North Dakota State Investment Board recently acquired 60,762 shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, valuing their new positi...
Bullish
AbbVie Inc. is drawing investor attention in May 2026 due to new clinical data for its immunology drug Skyrizi in inflammatory arthritis and its consi...
Bullish
AbbVie Inc. has reported stronger-than-expected first-quarter 2026 results, with net revenues reaching $15.0 billion and adjusted earnings per share h...
Neutral
Pure Financial Advisors LLC increased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 74.6% during the fourth quarter, according to its most rec...
Bullish
AbbVie Inc. reported strong double-digit revenue growth in Q1 2026, driven primarily by its immunology drugs Skyrizi and Rinvoq, and its aesthetics po...
Bullish
AbbVie, in partnership with adMare BioInnovations, recognized RIME Therapeutics with the AbbVie Biotech Innovators Award for its innovative "Disruptid...
Neutral
Artemis Investment Management LLP significantly decreased its holdings in AbbVie Inc. by 10.1% in the fourth quarter, reducing its stake to 703,998 sh...
Bullish
AbbVie announced a $1.4 billion investment to construct a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. This state-of-the-ar...
Neutral
AbbVie (ABBV) is set to announce its earnings tomorrow before market hours. The market anticipates a 10.5% year-on-year revenue growth, an increase fr...
Bearish
AbbVie Inc. (ABBV) announced it received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for trenibotulinumt...
Neutral
Sanctuary Advisors LLC increased its stake in AbbVie Inc. by 1.5% in the fourth quarter, purchasing an additional 6,911 shares, bringing its total hol...
Neutral
AbbVie (ABBV) has seen its share price soften recently, declining 10.55% year-to-date, despite strong longer-term returns. A popular valuation narrati...